Comparison of the Efficacy and Safety of SGLT2i and GLP-1 Receptor Agonists in Obese Patients With Kidney Disease

Conditions: Obesity; Chronic Kidney Diseases Interventions: Drug: RAS inhibitors ：Losartan®️/Valsartan®️; Drug: dapagliflozin：Forxiga®️; Drug: simagliptin：Forxiga®️ Sponsors: RenJi Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials